Pacific Biosciences (NASDAQ:PACB) shares traded 0% up during most recent session to reach at the closing price of $7.3. The stock exchanged hands 441191 shares versus average trading capacity of 1.7 Million shares, yielding a market cap of $1.11 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $6.67 within the next 52-weeks. The mean target projections are based on 6 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Pacific Biosciences (NASDAQ:PACB) high price target of $8 and with a conservative view have low price target of $3.5.
Cowen & Co. “Downgrades” Pacific Biosciences (NASDAQ:PACB) in a research note issued to investors on 1/04/19 to Market Perform with price target of $0.
Additionally on 11/12/18 Cantor Fitzgerald “Downgrades” Pacific Biosciences (NASDAQ:PACB) to Neutral setting price target at $0 and on 10/19/18 Cowen & Co. “Initiates Coverage On” the stock to Outperform at $6.5. Furthermore on 8/09/18 Cantor Fitzgerald “Initiates Coverage On” the stock to Overweight at $5.
On the other hand the company has Relative Strength Index (RSI 14) of 52.21 along with Average True Range (ATR 14) of 0.09, Consequently Pacific Biosciences (NASDAQ:PACB)’s weekly and monthly volatility is 0.88%, 1.12% respectively. The company’s beta value is at 2.4.
In terms of Buy, Sell or Hold recommendations, Pacific Biosciences (NASDAQ:PACB) has analysts’ mean recommendation of 2.7. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Pacific Biosciences (NASDAQ:PACB)’s minimum EPS for the current quarter is at $-0.2 and can go high up to $-0.11. The consensus mean EPS for the current quarter is at $-0.15 derived from a total of 5 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.2 earnings per share for the same quarter during last year.
Previously Pacific Biosciences (NASDAQ:PACB) reported $-0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.13 by $-0.08. The company posted an earnings surprise of -61.5%.
Pacific Biosciences (NASDAQ:PACB)’s revenue estimates for the current quarter are $22.22 Million according to 4 number of analysts, for the current quarter the company has high revenue estimates of $23.4 Million in contradiction of low revenue estimates of $21.5 Million. For the current year the company’s revenue estimates are $111.66 Million compared to low analyst estimates of $97.4 Million and high estimates of $119.55 Million according to 5 number of analysts.
Currently Pacific Biosciences (NASDAQ:PACB)’s shares owned by insiders are 2.3%, whereas shares owned by institutional owners are 74.8%. However the six-month change in the insider ownership was recorded -1.82%, as well as three-month change in the institutional ownership was recorded -10.29%.
Pacific Biosciences (NASDAQ:PACB)’s trailing twelve month revenues are $78.6 Million, whereas its price to sales ratio for the same period is 14.06. Its book value per share for the most recent quarter is $0.76 while its price to book ratio for the same period is 9.61, as for as the company’s cash per share for the most recent quarter is $0.68, however its price to cash per share ratio for the same period is 10.8. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.